Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

1. Mateos, M.V.
2. Weisel, K.
3. Terpos, E.
4. Delimpasi, S.
5. Kastritis, E.
6. Zamagni, E.
7. Delforge, M.
8. Ocio, E.
9. Katodritou, E.
10. Gay, F.
11. Larocca, A.
12. Leleu, X.
13. Otero, P.R.
14. Schjesvold, F.
15. Cavo, M.
16. Dimopoulos, M.A.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.3324/HAEMATOL.2023.284694 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus